Abstract Library

#2980 Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors

Introduction: The circadian clock genes encode transcription factors whose interaction with nuclear receptors allows the regulation of cellular metabolism.The invalidation of the genes of the clock core is associated with the development of many endocrine diseases including neuroendocrine cancer. Recently, the family of transcriptional coactivators PGC-1a has been identified as a key element in the integration of cellular metabolic state with the circadian clock. PRC, as a member of the PGC-1 family, was able to interact with several transcription factors, including the CLOCK factor. The specific induction of this PRC factor by the cell cycle, to modulate the energy function, the MAPkinase pathway and the expression of microRNAs, makes it a key factor in the metabolic adaptation of cancer cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Savagner F

Authors: Savagner F, Le Pennec S,

Keywords: Metabolism, Circadian clock, cell models,

#2275 Analysis of Gene Expression Patterns of Rectum Neuroendocrine Tumors (NET) Versus Healthy Tissue Reveals Alterations in the MAPK and WNT Signaling Pathways

Introduction: The neuroendocrine tumors (NETs) of the rectum are rare but increasing in incidence, by means of improved endoscopic techniques and histological reporting. They often occur as small polypoid lesions and G1, and in most cases an incidental finding at endoscopy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Hummel M, Grabowski P, Arsenic R,

Keywords: rectum neuroendocrine tumors, NET, MAP kinase, gene expression analysis, Wnt signaling,

#1737 The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer

Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hoffmann J, Corbett L, Detjen K, Thedieck K, Sers C,

Keywords: pancreatic neuroendocrine tumors, MAPK pathway,

#1003 Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block

Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lewens F

Authors: Lewens F, Freitag H, Briest F, Heilmann M, Schneider C,

Keywords: bronchial, NETs, PI3K, FoxM1, survivin, cell lines, SCLC,

#874 The pan-TRK Inhibitor GNF5837 Inhibits Cell Viability and Akt and MAPK Signaling in Human Neuroendocrine GOT1 Tumor Cells

Introduction: The tropomyosin receptor kinase family (TRKA, TRKB, TRKC) effects tumor cell growth in various models. Recent preclinical studies in neuroendocrine carcinoma of the lung cell lines have shown that Trk receptors might be a therapeutic target for neuroendocrine neoplasias.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Heinzle V, Reuther C, Spöttl G, Maurer J, Göke B,

Keywords: neuroendocrine tumor, trk receptor,